Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Clin Cancer Res. 2017 Apr 26;23(16):4680–4692. doi: 10.1158/1078-0432.CCR-16-3029

Figure 4.

Figure 4

A, (left) Average tumor sizes in animals treated with XL147, R788, or both (N = 7). Values are shown as mean +/− S.E.M. ranges. (right) CBRC013 PDX tumor sizes after three weeks of treatment. B, (left) Average CBRC029 tumor sizes in animals treated with perifosine, R788, or both (N = 7–8). Values are shown as mean +/− S.E.M. ranges. (right) CBRC029 PDX tumor sizes after three weeks of treatment. C, (left) Average CBRC029 tumor sizes in animals treated with perifosine, fingolimod, or both (N = 8). Values are shown as mean +/− S.E.M. ranges. (right) CBRC029 PDX tumor sizes after three weeks of treatment. D, (left) Average CBRC029 tumor sizes in animals treated with dasatinib, tozasertib, or both (N = 3–7). Values are shown as mean +/− S.E.M. ranges. (right) CBRC029 PDX tumor sizes after three weeks of treatment.